Cigna Group (CI)
(Delayed Data from NYSE)
$353.18 USD
+0.79 (0.22%)
Updated Apr 22, 2024 04:00 PM ET
After-Market: $353.17 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$353.18 USD
+0.79 (0.22%)
Updated Apr 22, 2024 04:00 PM ET
After-Market: $353.17 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Zacks News
Here's Why Cigna (CI) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why the Market Dipped But Cigna (CI) Gained Today
by Zacks Equity Research
Cigna (CI) closed at $348.78 in the latest trading session, marking a +0.78% move from the prior day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Cigna (CI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
UnitedHealth Group (UNH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 4.22% and 0.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) Stock Moves -0.92%: What You Should Know
by Zacks Equity Research
Cigna (CI) reachead $349.84 at the closing of the latest trading day, reflecting a -0.92% change compared to its last close.
Acadia Healthcare (ACHC) Opens Facility to Address Mental Health
by Zacks Equity Research
Acadia Healthcare (ACHC) inaugurates an acute care hospital in Mesa, AZ, to cater to patients struggling with addiction and mental health issues in the area.
Here's Why Cigna (CI) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Brookdale Senior (BKD) Sees Y/Y Increase in Q1 Occupancy Levels
by Zacks Equity Research
Brookdale Senior (BKD) witnesses 29 straight months of year-over-year increases in weighted average occupancy level.
CI vs. HUM: Which Stock Is the Better Value Option?
by Zacks Equity Research
CI vs. HUM: Which Stock Is the Better Value Option?
Compelling Reasons to Hold Acadia Healthcare (ACHC) Stock Now
by Zacks Equity Research
Growing commercial, Medicare and Medicaid revenues will likely boost Acadia Healthcare's (ACHC) top line.
Cigna (CI) Stock Moves -0.19%: What You Should Know
by Zacks Equity Research
Cigna (CI) closed the most recent trading day at $360.37, moving -0.19% from the previous trading session.
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?
by Zacks Equity Research
Here is how Adverum Biotechnologies (ADVM) and Cigna (CI) have performed compared to their sector so far this year.
5 Low Price-to-Sales Stocks Poised to Race up the Charts
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like KBH, AMG, CI, BBSI and JAKK hold promise.
Humana's (HUM) Medicaid Business Teams Up With CPESN USA in Ohio
by Zacks Equity Research
Humana's (HUM) partnership with CPESN USA in Ohio aims to overcome barriers like limited access to healthcare services in rural and underserved communities.
Select Medical (SEM) Expands in Florida With UF Health JV
by Zacks Equity Research
Select Medical (SEM) inks a joint venture agreement with UF Health Jacksonville to open a 48-bed inpatient rehabilitation hospital in Florida.
UnitedHealth's (UNH) Optum to Buy Steward's Physician Group
by Zacks Equity Research
UnitedHealth (UNH) unit Optum's acquisition of Steward Health's physician group is expected to close in the second quarter of 2024.
Top Research Reports for Walmart, Linde & IBM
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Linde plc (LIN) and International Business Machines Corporation (IBM).
Acadia (ACHC) Starts Construction of Malden's JV Facility
by Zacks Equity Research
Acadia Healthcare (ACHC) initiates the construction work of the 144-bed Massachusetts-based joint venture hospital in a bid to address the need for efficient behavioral health services in the region.
Here's How Much a $1000 Investment in Cigna Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Cigna (CI) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Cigna (CI) reachead $363.34 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.
Why Cigna (CI) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Brokers Suggest Investing in Cigna Group (CI): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Cigna Group (CI) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?